Full Text:   <993>

Summary:  <1049>

CLC number: 

On-line Access: 2021-05-07

Received: 2020-11-03

Revision Accepted: 2020-12-30

Crosschecked: 0000-00-00

Cited: 0

Clicked: 1869

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Zhaofeng LIANG

https://orcid.org/0000-0001-9799-0837

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2021 Vol.22 No.5 P.341-347

http://doi.org/10.1631/jzus.B2000711


Exosomes in bladder cancer: novel biomarkers and targets


Author(s):  Hao GENG, Qingchen ZHOU, Wenhao GUO, Ling LU, Liangkuan BI, Yi WANG, Jie MIN, Dexin YU, Zhaofeng LIANG

Affiliation(s):  Department of Urology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230032, China; more

Corresponding email(s):   dxyu@ahmu.edu.cn, liangzhaofeng@ujs.edu.cn

Key Words:  Exosome, Bladder cancer, Function, Clinical application, Biomarker


Share this article to: More |Next Article >>>

Hao GENG, Qingchen ZHOU, Wenhao GUO, Ling LU, Liangkuan BI, Yi WANG, Jie MIN, Dexin YU, Zhaofeng LIANG. Exosomes in bladder cancer: novel biomarkers and targets[J]. Journal of Zhejiang University Science B, 2021, 22(5): 341-347.

@article{title="Exosomes in bladder cancer: novel biomarkers and targets",
author="Hao GENG, Qingchen ZHOU, Wenhao GUO, Ling LU, Liangkuan BI, Yi WANG, Jie MIN, Dexin YU, Zhaofeng LIANG",
journal="Journal of Zhejiang University Science B",
volume="22",
number="5",
pages="341-347",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000711"
}

%0 Journal Article
%T Exosomes in bladder cancer: novel biomarkers and targets
%A Hao GENG
%A Qingchen ZHOU
%A Wenhao GUO
%A Ling LU
%A Liangkuan BI
%A Yi WANG
%A Jie MIN
%A Dexin YU
%A Zhaofeng LIANG
%J Journal of Zhejiang University SCIENCE B
%V 22
%N 5
%P 341-347
%@ 1673-1581
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000711

TY - JOUR
T1 - Exosomes in bladder cancer: novel biomarkers and targets
A1 - Hao GENG
A1 - Qingchen ZHOU
A1 - Wenhao GUO
A1 - Ling LU
A1 - Liangkuan BI
A1 - Yi WANG
A1 - Jie MIN
A1 - Dexin YU
A1 - Zhaofeng LIANG
J0 - Journal of Zhejiang University Science B
VL - 22
IS - 5
SP - 341
EP - 347
%@ 1673-1581
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000711


Abstract: 
exosomes are nanometer-sized vesicles that contain various types of biologically active components, including proteins, nucleic acids, carbohydrates, and lipids, which vary with the type and physiological state of the cell. In recent years, several studies have showed that exosomes can provide new non-invasive diagnostic and prognostic biomarkers in patients affected by cancers, including bladder cancer (BC), and the lipid bilayer membrane structure makes exosomes as promising delivery vehicles for therapeutic applications. exosomes have the characteristics of high abundance, high stability, tissue specificity, and wide distribution in body fluids, and are secreted as various types by cells in different states, thereby possessing great potential as biomarkers for BC. Herein, we briefly summarize the functions and roles of exosomes in the occurrence and development of BC and the current progress of research on exosomes in BC, while focusing on potential clinical applications of the diagnosis, treatment, and prognosis of BC.

外泌体与膀胱癌:新的生物标志物和靶点

概要:外泌体是纳米大小的囊泡,包含蛋白质、核酸、碳水化合物和脂质等各种生物活性成分,这些成分会随细胞的类型和生理状态而变化。近年来,一些研究表明不但外泌体可以为包括膀胱癌在内的多种肿瘤提供新的无创性诊断和预后生物标志物,而且外泌体脂质双层膜结构可使其成为治疗应用的理想载体。外泌体具有丰度高、稳定性好、组织特异性强,以及在体液中广泛分布等特点,且可以由在不同状态下的多种细胞所分泌。因此,外泌体具有作为膀胱癌诊断和预后生物标志物的巨大潜力。本文就外泌体在膀胱癌发生发展中的作用及其研究现状进行综述,并聚焦于外泌体在膀胱癌诊断、治疗和预后中的临床应用。

关键词:外泌体;膀胱癌;功能;临床应用;生物标志物

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]AbbastabarM, SarfiM, GolestaniA, et al., 2020. Tumor-derived urinary exosomal long non-coding RNAs as diagnostic biomarkers for bladder cancer. EXCLI J, 19:301-310.

[2]BeckhamCJ, OlsenJ, YinPN, et al., 2014. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol, 192(2):583-592.

[3]BerrondoC, FlaxJ, KucherovV, et al., 2016. Expression of the long non-coding RNA hotair correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS ONE, 11(1):e0147236.

[4]CaiHZ, YangXJ, GaoY, et al., 2019. Exosomal microRNA-9-3p secreted from BMSCs downregulates ESM1 to suppress the development of bladder cancer. Mol Ther Nucleic Acids, 18:787-800.

[5]CaiXX, QuLL, YangJ, et al., 2020. Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1. Cancer Med, 9(16):6009-6019.

[6]ChenCH, LuoYM, HeW, et al., 2020. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J Clin Invest, 130(1):404-421.

[7]ChenX, ChenRX, WeiWS, et al., 2018. PRMT5 circular RNA promotes metastasis of urothelial carcinoma of the bladder through sponging miR-30c to induce epithelial-mesenchymal transition. Clin Cancer Res, 24(24):6319-6330.

[8]ChristensenE, Birkenkamp-DemtröderK, SethiH, et al., 2019. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol, 37(18):1547-1557.

[9]de PalmaG, di LorenzoVF, KrolS, et al., 2019. Urinary exosomal shuttle RNA: promising cancer diagnosis biomarkers of lower urinary tract. Int J Biol Markers, 34(2):101-107.

[10]el AndaloussiS, MägerI, BreakefieldXO, et al., 2013. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov, 12(5):347-357.

[11]ElsharkawiF, ElsabahM, ShabayekM, et al., 2019. Urine and serum exosomes as novel biomarkers in detection of bladder cancer. Asian Pac J Cancer Prev, 20(7):2219-2224.

[12]FranzenCA, BlackwellRH, TodorovicV, et al., 2015. Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes. Oncogenesis, 4(8):e163.

[13]FranzenCA, BlackwellRH, ForemanKE, et al., 2016. Urinary exosomes: the potential for biomarker utility, intercellular signaling and therapeutics in urological malignancy. J Urol, 195(5):1331-1339.

[14]HuangCS, HoJY, ChiangJH, et al., 2020. Exosome-derived LINC00960 and LINC02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder cancer cells. Cells, 9(6):1419.

[15]LiQ, WangHL, PengHR, et al., 2019. MicroRNAs: key players in bladder cancer. Mol Diagn Ther, 23(5):579-601.

[16]LiQ, HuyanT, CaiSN, et al., 2020. The role of exosomal miR-375-3p: a potential suppressor in bladder cancer via the Wnt/β-catenin pathway. FASEB J, 34(9):12177-12196.

[17]LiangZF, LuL, MaoJH, et al., 2017. Curcumin reversed chronic tobacco smoke exposure induced urocystic EMT and acquisition of cancer stem cells properties via Wnt/β-catenin. Cell Death Discov, 8(10):e3066.

[18]LinF, YinHB, LiXY, et al., 2020. Bladder cancer cell-secreted exosomal miR-21 activates the PI3K/AKT pathway in macrophages to promote cancer progression. Int J Oncol, 56(1):151-164.

[19]MeariniE, PoliG, CochettiG, et al., 2017. Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer. Onco Targets Ther, 10:2665-2673.

[20]MiyamotoDT, MouwKW, FengFY, et al., 2018. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol, 19(12):e683-e695.

[21]PantelK, Alix-PanabièresC, 2010. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med, 16(9):398-406.

[22]PegtelDM, GouldSJ, 2019. Exosomes. Annu Rev Biochem, 88:487-514.

[23]PoliG, BrancorsiniS, CochettiG, et al., 2015. Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA. Urol Oncol Semin Orig Invest, 33(12):505.e1-505.e7.

[24]PoliG, CochettiG, BoniA, et al., 2017. Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy. Urol Oncol Semin Orig Invest, 35(12):674.e19-674.e24.

[25]PoliG, EgidiMG, CochettiG, et al., 2020. Relationship between cellular and exosomal miRNAs targeting NOD-like receptors in bladder cancer: preliminary results. Minerva Urol Nefrol, 72(2):207-213.

[26]Ringuette GouletC, BernardG, TremblayS, et al., 2018. Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGFβ signaling. Mol Cancer Res, 16(7):1196-1204.

[27]SiegelRL, MillerKD, JemalA, 2019. Cancer statistics, 2019. CA Cancer J Clin, 69(1):7-34.

[28]StreetJM, YuenPST, StarRA, 2014. Bioactive exosomes: possibilities for diagnosis and management of bladder cancer. J Urol, 192(2):297-298.

[29]WangJS, YangK, YuanWX, et al., 2018. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit, 24:9307-9316.

[30]WuCH, SilversCR, MessingEM, et al., 2019. Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of nonmalignant cells. J Biol Chem, 294(9):3207-3218.

[31]XueM, ChenW, XiangA, et al., 2017. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Mol Cancer, 16:143.

[32]YazarlouF, MowlaSJ, Kholghi OskooeiV, et al., 2018a. Urine exosome gene expression of cancer-testis antigens for prediction of bladder carcinoma. Cancer Manage Res, 10:5373-5381.

[33]YazarlouF, ModarressiMH, MowlaSJ, et al., 2018b. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. Cancer Manage Res, 10:6357-6365.

[34]YinXB, ZhengXP, LiuM, et al., 2020. Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells. Cell Biol Int, 44(4):958-965.

[35]YoshidaK, TsudaM, MatsumotoR, et al., 2019. Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer. Cancer Sci, 110(7):2119-2132.

[36]ZhanY, DuLT, WangLS, et al., 2018. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer, 17:142.

[37]ZhangSJ, DuLT, WangLS, et al., 2019. Evaluation of serum exosomal lncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer. J Cell Mol Med, 23(2):1396-1405.

[38]ZhengR, DuML, WangXW, et al., 2018. Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression. Mol Cancer, 17(1):143.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE